Ligand Pharmaceuticals LGND Revenue from intangible royalty assets — Total revenues and income

Other product segments

Similar metrics at other companies

RPRXIncome from financial royalty assets — Total income and other revenues

$594.99M+10.3%

INCYProduct royalty revenues — Total revenues

$151.19M+15.7%

BIIBRoyalty and other revenue — Total Revenue

$9.7M-11.8%

PFERoyalty — Revenue

$396M+28.6%

BMRNRoyalty and other revenues — Total revenues

$6.13M-41.6%

INCYOther product royalty revenues — Total revenues

$3.25M+156%

Questions, answered.

What is Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income?

Ligand Pharmaceuticals (LGND) reported revenue from intangible royalty assets — total revenues and income of $32.93M in Q1 2026.

How has Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income changed year-over-year?

Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income increased by 52.6% year-over-year, from $21.59M to $32.93M.

What is the long-term trend for Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income?

Over 3 years (2022 to 2025), Ligand Pharmaceuticals's revenue from intangible royalty assets — total revenues and income has grown at a 22.3% compound annual growth rate (CAGR), from $72.53M to $132.53M.

What does revenue from intangible royalty assets — total revenues and income mean?

This metric represents the total income generated from royalty streams associated with the company's portfolio of intangible pharmaceutical assets. It captures the recurring cash flows derived from licensing agreements and commercialized products developed through the company's technology platforms. This figure serves as a primary indicator of the long-term commercial success and market adoption of the drugs supported by the company's intellectual property.